Elands J, Barberis C, Jard S, Tribollet E, Dreifuss J J, Bankowski K, Manning M, Sawyer W H
Centre CNRS-INSERM de Pharmacologie-Endocrinologie, Montpellier, France.
Eur J Pharmacol. 1988 Mar 1;147(2):197-207. doi: 10.1016/0014-2999(88)90778-9.
An oxytocic antagonist, [1-(beta-mercapto-beta, beta-cyclopentamethylenepropionic acid,2-O-methyltyrosine,4-threonine, 8-ornithine,9-tyrosylamide]vasotocin (d(CH2)5[Tyr(Me)2, Thr4,Tyr-NH2(9)]OVT [corrected], was monoiodinated at the phenyl moiety of the tyrosylamide residue at position 9. 125I-labelling was performed with 1,3,4,6-tetrachloro-3 alpha,6 alpha-diphenyl-glycoluril. Iodination resulted in an increased affinity for rat uterine oxytocin receptors. A considerably lower affinity for rat vascular V1- and renal V2-receptors was found, resulting in a highly specific oxytocin receptor ligand. 125I-labelled d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT [corrected] was demonstrated to bind selectively to one population of binding sites in rat uterus and ventral hippocampal membrane preparations. Dissociation constants ranged between 0.03 and 0.06 nM. After 3 days of exposure autoradiography revealed binding in regions known to contain oxytocin receptors as well as labelling in some new regions, while no binding was found in the lateral septum, a structure containing mainly [8-arginine]vasopressin receptors. The high specific radioactivity of 125I-labelling allowed important reductions in membrane protein amount, gain in precision of binding analysis as well as considerably lower exposure times for autoradiography.
一种催产素拮抗剂,[1-(β-巯基-β,β-环五亚甲基丙酸),2-O-甲基酪氨酸,4-苏氨酸,8-鸟氨酸,9-酪氨酰胺]血管加压素(d(CH2)5[Tyr(Me)2, Thr4,Tyr-NH2(9)]OVT[已校正]),在第9位酪氨酰胺残基的苯基部分进行了单碘化。用1,3,4,6-四氯-3α,6α-二苯基甘脲进行125I标记。碘化导致对大鼠子宫催产素受体的亲和力增加。发现对大鼠血管V1和肾V2受体的亲和力相当低,从而产生了一种高度特异性的催产素受体配体。125I标记的d(CH2)5[Tyr(Me)2,Thr4,Tyr-NH2(9)]OVT[已校正]被证明能选择性地结合大鼠子宫和腹侧海马膜制剂中的一类结合位点。解离常数在0.03至0.06 nM之间。暴露3天后,放射自显影显示在已知含有催产素受体的区域有结合,同时在一些新区域也有标记,而在主要含有[8-精氨酸]加压素受体的外侧隔区未发现结合。125I标记的高比放射性使得膜蛋白用量大幅减少,结合分析的精度提高,以及放射自显影的曝光时间大大缩短。